Proteomic Analysis of Metastasis-Specific Biomarkers in Pancreatic Cancer: Galectin-1 Plays an Important Metastatic Role in Pancreatic Cancer

Tung, Chun‐Liang; Lin, Ming-Tzer; Hu, Ren-Yu; Chien, Yi-Chun; Liao, En‐Chi; Lin, Li‐Hsun; Chung, Ting-Wen; Wei, Yu‐Shan; Tsai, Yi‐Ting; Chen, Hsin‐Yi; Chou, Hsiu‐Chuan; Kuo, Wen‐Hung; Ko, Mei–Lan; Chang, Shing‐Jyh; Lee, Ying‐Ray; Chan, Hong‐Lin

doi:10.1016/j.jpba.2020.113300

Cited by 5 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Ms-based Protein Biomarkers For Pdacmentioning

confidence: 99%

“…In SILAC-DDA MS method, PGAM1, cadherin-3 (CDH3), plasminogen activator urokinase (PLAU), and lunatic fringe (LFNG) were suggested as potential therapeutic target. [123,125] Leukemia inhibitory factor (LIF), LGALS1, TIMP1, ALDH1A1, and GSN were also discovered with therapeutic significance using PRM-based MS and MALDI-TOF MS. [118,124,132,133] Moreover, several proteins, including LGALS3BP, MMP2, CTSD, SERPINE1, BGN, TIMP2, and LGALS1, were identified as potential therapeutic targets, showcasing the proteome complexity in PDAC. [120] In the PTM level, Cao et al [119] uncovered potential therapeutic targets through phosphoproteomics analysis and identified glycoproteins for early detection in PDAC via TMT labeling, including sialyltransferase (ST6GAL1, ST3GAL1), fucosyltransferase (FUT3, FUT11), and galactosyltransferase (B4GALT4, B4GALT1).…”

Section: Prognostic Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Mass spectrometry–based proteomics technology in pancreatic cancer research

Sun,

Wang,

Wong

2023

Journal of Pancreatology

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) has become a significant health concern with increasing incidence and mortality rates over the past few decades. Researchers have turned their attention to cutting-edge mass spectrometry (MS) technology due to its high-throughput and accurate detection capacity, which plays a vital role in understanding the mechanisms and discovering biomarkers for pancreatic diseases. In this review, we comprehensively investigate various methodologies of quantitative and qualitative proteomics MS technologies, alongside bioinformatical platforms employed in pancreatic cancer research. The integration of these optimized approaches provides novel insights into the molecular mechanisms underlying tumorigenesis and disease progression, ultimately facilitating the discovery of potential diagnostic, prognostic biomarkers, and therapeutic targets. The robust MS-based strategy shows promise in paving the way for early diagnosis and personalized medicine for pancreatic cancer patients.

show abstract

Section: Ms-based Protein Biomarkers For Pdacmentioning

confidence: 99%

Section: Prognostic Biomarkersmentioning

confidence: 99%

Mass spectrometry–based proteomics technology in pancreatic cancer research

Sun,

Wang,

Wong

2023

Journal of Pancreatology

View full text Add to dashboard Cite

show abstract

Section: Galectin-1 and Lymph Node Metastasis In Pancreatic Cancermentioning

confidence: 99%

“…Galectin-1 expression in pancreatic cancer demonstrates a significant association with the disease's progression and metastasis, particularly in lymph node metastases [75]. Compared to normal pancreatic tissues, Gal-1 expression has been found to be substantially higher in both primary malignant tumors and metastatic tissues [75]. This increase appears even more pronounced in advanced lymph node metastases, highlighting a potentially critical role for Gal-1 in pancreatic cancer's invasive nature [72,75].…”

Section: Galectin-1 and Lymph Node Metastasis In Pancreatic Cancermentioning

confidence: 99%

Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities

Bogut,

Stojanovic,

Jovanovic

et al. 2023

IJMS

View full text Add to dashboard Cite

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1’s involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.

show abstract

“…Galectin-1 (Gal1) is one of the 15 members of the beta-galactose-binding proteins, galactoagglutinins. Recent studies have demonstrated that Gal1 is expressed in a variety of malignant tumors, including hepatocellular carcinomas [ 7 ], lung adenocarcinomas [ 8 ], pancreatic cancers [ 9 ], breast cancers [ 10 ], colon cancers [ 11 ], and GC [ 12 ]. It is mainly distributed in the extracellular matrix and cytoplasm, and regulates various biological activities of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Galectin-1-mediated high NCAPG expression correlates with poor prognosis in gastric cancer

Zheng

Tao

Zhou

et al. 2023

Aging

View full text Add to dashboard Cite

Galectin-1 (Gal1) and non-SMC condensin I complex, subunit G (NCAPG) are associated with metastasis in several malignant tumors. However, their precise roles in gastric cancer (GC) remain uncertain. This study explored the clinical significance and relationship of Gal1 and NCAPG in GC. Gal1 and NCAPG expressions were significantly up-regulated in GC compared to adjacent non-cancerous tissues by immunohistochemistry (IHC) and Western blotting. Besides, methods including stable transfection, quantitative real-time reverse transcription PCR, Western blotting, Matrigel invasion and wound-healing assays in vitro , were also conducted. IHC scores for Gal1 and NCAPG had a positive correlation in GC tissues. High Gal1 or NCAPG expression significantly correlated with poor prognosis in GC, and Gal1 combined with NCAPG had a synergetic effect on the prediction of GC prognosis. Gal1 overexpression in vitro enhanced NCAPG expression, cell migration, and invasion in SGC-7901 and HGC-27 cells. Simultaneous Gal1 overexpression and NCAPG knockdown in GC cells partly rescued the migrative and invasive abilities. Thus, Gal1 promoted GC invasion through increased NCAPG expression. The present study demonstrated the prognostic significance of the combination of Gal1 and NCAPG in GC for the first time.

show abstract

Proteomic Analysis of Metastasis-Specific Biomarkers in Pancreatic Cancer: Galectin-1 Plays an Important Metastatic Role in Pancreatic Cancer

Cited by 5 publications

References 11 publications

Mass spectrometry–based proteomics technology in pancreatic cancer research

Mass spectrometry–based proteomics technology in pancreatic cancer research

Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities

Galectin-1-mediated high NCAPG expression correlates with poor prognosis in gastric cancer

Contact Info

Product

Resources

About